Technical validation of an autoantibody test for lung cancer

A. Murray1, C. J. Chapman2, G. Healey1, L. J. Peek3, G. Parsons4, D. Baldwin5, A. Barnes3, H. F. Sewell6, H. A. Fritsche7 & J. F. R. Robertson2*

1Oncimmune Ltd; 2Division of Breast Surgery, University of Nottingham, Clinical Sciences Building, Nottingham City Hospital, Nottingham, UK; 3Oncimmune LLC, De Soto, KS; 4Parsons Group LLC, Arlington, MA, USA; 5Department of Respiratory Medicine, Nottingham City Hospital; 6Division of Immunology, School of Molecular Medical Sciences, Medical School, Queens Medical Centre, Nottingham, UK and 7Department of Laboratory Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA

Received 9 October 2009; accepted 11 December 2009

Background: Publications on autoantibodies to tumour-associated antigens (TAAs) have failed to show either calibration or reproducibility data. The validation of a panel of six TAAs to which autoantibodies have been described is reported here.

Materials and methods: Three separate groups of patients with newly diagnosed lung cancer were identified, along with control individuals, and their samples used to validate an enzyme-linked immunosorbent assay. Precision, linearity, assay reproducibility and antigen batch reproducibility were all assessed.

Results: For between-replicate error, samples with higher signals gave coefficients of variation (CVs) in the range 7%–15%. CVs for between-plate variation were only 1%–2% higher. For between-run error, CVs were in the range 15%–28%. In linearity studies, the slope was close to 1.0 and correlation coefficient values were generally >0.8. The sensitivity and specificity of individual batches of antigen varied slightly between groups of patients; however, the sensitivity and specificity of the panel of antigens as a whole remained constant. The validity of the calibration system was demonstrated.

Conclusions: A calibrated six-panel assay of TAAs has been validated for identifying nearly 40% of primary lung cancers via a peripheral blood test. Levels of reproducibility, precision and linearity would be acceptable for an assay used in a regulated clinical setting.

Key words: autoantibodies, diagnostic test, lung cancer, tumour-associated antigens

introduction

Lung cancer is the highest cause of death from cancer worldwide, responsible for the deaths of >1 million men and women every year [1]. Lung cancer is often detected on chest X-ray, but by this time, the cancer is usually advanced and few patients are cured by treatment. However, if diagnosed early, the chances of cure are ~90%. At present, there is no early detection test or acceptable screening method for this disease; therefore, there is an urgent need to produce a screening test that can identify the cancer in its early curable stage, especially in high-risk individuals.

Circulating antibodies which react with tumour-associated antigens (TAAs) have been found in serum samples from patients with a variety of cancers, including lung cancer [2–10], and may represent an early indicator of the presence of cancer. It has been hypothesised that the heterogeneity of antigen expression will mean that a panel of assays for autoantibodies to various TAA specificities will be needed for effective detection of lung cancer [11]. Recent publications have confirmed that measuring autoantibodies to a panel of antigens gives a significantly greater level of sensitivity compared with that for a single antigen [5–10].

Autoantibodies have been found in the blood of patients who develop lung cancer up to 5 years before screening spiral computed tomography scans were able to detect the tumour [2]. Consequently, monitoring people at increased risk of lung cancer for the presence of serum autoantibodies may enable earlier detection of the disease, allowing earlier therapeutic intervention.

This article reports the laboratory validation data and performance characteristics for a serum autoantibody test panel consisting of six TAAs to which autoantibodies have been described. The antigens are p53, NY-ESO-1, cancer-associated antigen (CAGE), GBU4-5, Annexin 1 and SOX2, and the samples are from patients with or without newly diagnosed lung cancer. Specifically, we address the development of quality assurance in reagent preparation, analyte calibration and quality-control (QC)
protocols, which are required of a serum autoantibody panel test carried out in a clinical laboratory setting.

**materials and methods**

**production of recombinant antigens for autoantibody assays**

_**vector construct.** Specific complementary DNA (cDNA) for p53, NY-ESO-1, CAGE, GBU-4 and Annexin 1 were sub-cloned into the pET21b expression vector (which had previously been engineered to also express a BirA tag). The specific cDNA for SOX2 was sub-cloned into the pET44b expression vector (expressing a NusA tag) (Novagen, Darmstadt, Germany).

_expression of recombinant proteins/antigens._ The recombinant proteins were expressed in BL21(DE3) bacteria (Novagen), grown in terrific broth (TB) or autoinduction TB media (Novagen), and purified using HisTrap affinity columns (GE Healthcare, Uppsala, Sweden) according to manufacturers’ protocols. Negative control proteins consisting of either BirA or NusA alone were also produced. Antigen were produced by one of the two external manufacturers, except in the case of one study for which SOX2 was produced by Oncimmune Ltd. Details of the antigens used for each study are given in the supplemental Table S1 (available at Annals of Oncology online).

**patients**

Three separate groups of patients with newly diagnosed lung cancer were identified (supplemental Table S1, available at Annals of Oncology online). Group 1 contained 145 lung cancer patients (median age 66; range 41–87) and 146 normal controls (median age 66; range 41–87). Similarly, group 2 had 241 (63; 28–87) and 240 (63; 28–87), respectively, while group 3 had 269 (65; 38–87) and 269 (65; 38–86). All patients with lung cancer were as far as possible individually matched by sex, age and smoking history to a control individual with no previous history of malignant disease. In patients with lung cancer, blood samples were obtained after diagnosis but before receiving any anticancer treatment. Samples were obtained, with full informed consent, from the enrolment sites.

**assay procedure**

A semi-automated indirect enzyme-linked immunosorbant assay was utilised (all liquid-handling steps were carried out using an automated liquid-handling system). Purified recombinant antigens were diluted to provide a semi-log titration series for each antigen ranging from 160 to 1.6 nM. Control antigens (BirA and NusA) were also included to allow subtraction of the signal due to nonspecific binding to bacterial contaminants. Antigen dilutions were passively adsorbed to the surface of microtitre plate wells in high phosphate buffer overnight at room temperature. After washing in phosphate-buffered saline containing 0.1% Tween 20 (pH 7.6), microtitre plates were blocked with a gelatine-based blocking buffer. Coated plates were found to be stable for at least 48 h after coating if washed and stored at 4°C in the presence of blocking buffer (Oncimmune Ltd, data on file). Serum samples (diluted 1 in 110 in a blocking buffer) were then added to the plates and allowed to incubate at room temperature with shaking for 90 min. Following incubation, plates were washed and horseradish peroxidase (HRP)-conjugated rabbit anti-human IgG (Dako, Glostrup, Denmark) was added. After a 60-min incubation with shaking, the plates were washed and 3,3′,5,5′-tetramethylbenzidine was added. The optical density (OD) of each well was determined spectrophotometrically at 650 nm after a 15-min incubation. Control plates to which antigen-specific mAbs or an anti-His tag mAb (Novagen) had been added in place of serum were included to validate that the plate coating had been successful and antigen immunoreactivity had been maintained. These plates were probed with rabbit anti-mouse Ig-HRP (Dako).

_calibration._ Calibration standards of known potency are not available for assays to measure autoantibodies against TAAs. Therefore, a calibration system was devised in which fluids that drained from pleural or ascitic cavities of patients with lung cancer were screened for autoantibody reactivity [12]. Those found to be positive for the TAAs of interest were taken forward for further development. Specificity of the autoantibody reactivity in these fluids was assessed with recombinant TAAs and confirmed by western blotting. For each fluid, a calibration curve of background-corrected OD versus log dilution was constructed to which a four-parameter logistic model plot was fitted (median $r^2 > 0.99$) [13]. The OD value for each unknown sample was then converted to a calibrated log reference unit (RU) using the calibration curve. An optimum dilution range for each antigen was determined in order to give acceptable calibration precision (<20%). The range corresponded to 7.5%–92.5% of the upper asymptote of the average calibration curve, giving a range of 5.0 natural log units.

Apart from the validation studies, the calibration system was only evaluated for group 3 samples. A calibration curve was prepared at the beginning of every assay run.

**test result**

Samples were judged to be positive for the presence of autoantibody when they (i) showed a dose response to the antigen titration series and (ii) had a signal which was above the accepted cut-point for an assay to one or more of the antigens. Cut-points were originally derived in terms of ODs (mean ± 3 SD) but then in terms of RUs when the calibration system had been developed. A positive test result for the panel was defined as a positive autoantibody response to at least one of the six TAA antigens in the panel.

**assay validation**

_precision._ The intra-assay precision for this assay was on the basis of variation between replicates on the same plate (within plate) and between-plate run on the same day (between plate). Interassay precision (intermediate ‘between-run’ reproducibility) for each antigen in the assay was on the basis of variation over days within the same study (between run).

_Variance components and coefficients of variation (CVs) were estimated using standard analysis of variance methods. Separate calculations were carried out on antilogged RU values for samples with high, medium and low signals. The high and medium signals generally spanned the diagnostic test cut-point values.

Since independent reference materials of known concentration were not available for these assays, it was not possible to assess accuracy.

_linearity._ Linearity was assessed by a serum dilution study using two serum samples for each of the six antigens under the assumption that the top concentration gave 100% recovery. A doubling dilution series was prepared for each sample. The panel of autoantibody assays was carried out on each dilution and the OD measured. The dilution was estimated from the relevant calibration curve and a plot of the estimated versus the actual (known) dilution was constructed. The slope and intercept were estimated using linear regression and the goodness of fit assessed using the linear correlation coefficient. A slope of between 0.8 and 1.2, an intercept within 0.1 of zero and a correlation coefficient of at least 0.8 were required for satisfactory linearity.

_QC monitoring._ Six high-signal QC serum samples, one for each antigen, were interspersed amongst test samples in a series of studies carried out over a 14-week period. The results were compared with their respective expected values as established in preliminary studies. This enabled the QC sera to be monitored over time to evaluate their reproducibility using Levey–Jennings plots. The usual mean ± 3 SD chart limits were adjusted to mean ± 3.5 SD for the QC of six separate antigens.

_assay reproducibility._ The sensitivity and specificity for lung cancer of each of the individual autoantibody assays as well as the panel were assessed for each of
results

precision

For measurement of within-plate variation, samples with high signals gave CVs in the range 7%–15% (Table 1).

As expected, for samples with medium signals, CVs were higher, in the range 9%–23%. Samples with low signals (not presented) generally gave CVs > 20%, increasing as the mean OD approached zero.

For between-plate variation (not presented), CVs were only 1%–2% higher than for between-replicate error, indicating very little additional variability due to plate-to-plate differences.

For measurement of between-run variation, high-signal samples gave an average CV of 19% (range 15%–28%) (Table 1). Again as expected, for samples with medium signals, the average CV was higher at 28% (range 22%–42%). Samples with low signals generally gave CVs > 30%. These figures indicate significant additional variation due to run-to-run effects, increasing the CV by roughly 10% (Table 1). This amount is typical for assay work.

linearity

For all samples, the slope estimate was close to 1.0 and the intercept close to zero (Table 2; Figure 1), thereby indicating a linear assay. Correlation coefficients (r) were >0.83 in all but one case (Annexin 1: sample C6; r = 0.77), with a median of 0.98, thereby demonstrating satisfactory goodness of fit.

QC monitoring

The plots of calibrated results (RUs) versus time (Figure 2) showed that all QC serum control values for each of the six antigens fell within the standard deviation limits, demonstrating that the calibration system was effective in producing stable day-to-day QC results.

assay reproducibility

The sensitivity and specificity of each autoantibody assay as well as the panel for each of the sample groups are summarised in the supplemental Table S2 (available at *Annals of Oncology* online). The overall panel sensitivities and specificities were very similar between groups, demonstrating the validity of the calibration system and the robustness of the assay.

Using concordance data, the reproducibility of the calibrated panel (group 3) was confirmed as >95%. The number of samples that changed status (i.e. positive or negative) ranged from 0.5% to 2.4% per antigen. When categorised by cancer or

Table 1. Between-replicate precision and intermediate reproducibility estimates

| Sample | Initial OD | Slope, intercept | CVe (%) | CVr (%) |
|--------|------------|------------------|---------|---------|
| p53    | 0.17       | 0.38             | 11      |
| SOX2   | 0.31       | 0.38             | 11      |
| NY-ESO-1 | 0.35   | 0.69             | 11      |
| CAGE   | 0.23       | 0.43             | 7       |
| GBU4-5 | 0.10       | 0.35             | 9       |
| Annexin 1 | 0.13 | 0.25             | 15      |
| Average| 0.15       | 0.28             | 11      |

OD means on the basis of ~216 observations and 12 runs each; CVs on the basis of mean of two replicates of antilogged RU values. OD, optical density; CVe, between-replicate CV; CVr, between-run CV (including intra-assay component); CVs, coefficients of variation; RU, reference unit.

Table 2. Linearity analysis: summary by antigen and sample

| Sample | Initial OD | Slope, intercept | r   |
|--------|------------|------------------|-----|
| p53    | 0.20       | 0.83, 0.13       | 0.91|
| SOX2   | 0.06       | 0.97, –0.10      | 0.86|
| CAGE   | 0.90       | 0.97, 0.06       | 0.99|
| NY-ESO-1 | 0.49 | 0.98, 0.06      | 0.98|
| GBU4-5 | 0.19       | 0.93, 0.00       | 0.94|
| Annexin 1 | 0.31 | 0.96, 0.04      | 0.98|

Average standard error of the slope estimate = 0.09. OD, optical density; r, correlation coefficient.

*Background-corrected OD at initial dilution.
normal, the figures were 0%–2.6% and 0.4%–2.2%, respectively.

**Antigen batch reproducibility**

The characteristics of the assays run on a subset of group 3 samples using four different batches of CAGE antigen are summarised in Table 3. The mean calibrated signals for cancers and normal groups were similar across batches, demonstrating the effectiveness of the calibration system. The sensitivity and specificity of individual batches of antigen was also very similar, as was the sensitivity and specificity of the panel of antigens as a whole, demonstrating the robustness of an assay on the basis of a panel approach.

**Discussion**

Assays used to measure serum antibodies for the diagnosis and management of autoimmune disease often employ World Health Organization (WHO) standards as calibration materials [14,15]. These are usually derived from human serum or plasma (WHO website: http://www.who.int/bloodproducts/ref_materials/en/). As such, issues of longevity arise with new...
standard materials needing to be sourced, validated and introduced on a regular basis.

The fluids used as calibrator material in our study were drained from the pleural cavities of patients suffering from lung cancer as part of the normal course of their disease management. Use of these fluids provided a long-term source of calibrator material so that the inevitable difficulties encountered with sourcing and validating new materials could be avoided for as long as possible and the reproducibility of the assay result over months or even years could be assured. Although every effort was made to ensure that the fluids were stored under conditions that would not allow their reactivity to deteriorate, a study is underway to investigate the stability of pleural fluids as calibrator materials under long-term storage.

The optimised dilution of sera used (Oncimmune Ltd, data on file), together with the use of an anti-human IgG-HRP conjugate detection system, is considered important in the development of this test. They optimise detection of relevant autoantibodies while minimising detection of low-titre nonspecific antibodies (known to accumulate with advancing age) and poly-reactive IgM antibodies [16, 17].

Linearity is often difficult to demonstrate in serology assays and can show wide variability between assays [18]. However, we report good assay linearity with a slope close to 1 and a high correlation coefficient for all samples. We have also shown that the assay has CVs generally \(<15\%\) and \(<25\%\) for intra- and interassay precision, respectively. This is in line with that reported for measurement of serum autoantibodies in patients with benign autoimmune disease [19, 20]. Three discrete sets of clinical samples (totalling 655 cancers and 655 normals) were used for clinical validation of the assay. The sensitivity and specificity was shown to be in the region of 40% and 90%, respectively, for all three groups, demonstrating the reproducibility and robustness of this assay system. The fact

Figure 2. Levey–Jennings plots of control sera for each antigen over a 14-week period.
The performance characteristics of an assay for the measurement of autoantibodies against a panel of antigens known to be expressed in lung cancer have confirmed its reproducibility for identifying almost 40% of primary lung cancers through a peripheral blood test. The similar sensitivities and specificities measured for these three datasets and with different batches of proteins utilised in the assays emphasise the robustness of these autoantibody assays.

These data also confirm the value of a panel of autoantibodies over a single autoantibody assay. The small variations in sensitivity and specificity of single antigens between different studies could be attributed to the use of completely different sample sets. However, the attraction of the panel approach is that when the same antigens are used, the overall sensitivity and specificity remains constant even in discrete populations.

We have also shown reproducibility between four batches of an antigen (CAGE) in the calibrated assay. This shows stability of the results between protein batches. These data have allowed us to devise formal procedures for antigen batch verification and release that will ensure that all the required QC criteria are met and that an antigen batch is validated before it is released for use in the assay. This will ensure continuity of results across multiple antigen batches.

**conclusions**

The performance characteristics of an assay for the measurement of autoantibodies against a panel of antigens known to be expressed in lung cancer have confirmed its reproducibility for identifying nearly 40% of primary lung cancers through a peripheral blood test. The levels of reproducibility, precision and linearity would be acceptable for an assay used in a regulated clinical setting. A simple blood test that is both reliable and reproducible, such as that described here, represents a potential aid to imaging modalities. This assay has now been commercialised and will be used as a ‘platform technology’ that is technically valid for identifying all types of solid tumours.

**funding**

Oncimmune Ltd. Funding to pay the Open Access publication charges for this article was provided by The University of Nottingham and Oncimmune Ltd.

**acknowledgements**

P. Maddison is gratefully acknowledged for the provision of samples. J. Halsey is gratefully acknowledged for advice, valuable technical suggestions and comments on the manuscript. The manuscript was drafted by the authors. However, the authors would acknowledge and thank Sandra Cusco, from Complete Medical Communications, who provided final editorial assistance funded by Oncimmune Ltd.

**disclosure**

CC and JFRR are consultants to Oncimmune Ltd, a University of Nottingham spinout company. HAF, HFS and GP are members of the Oncimmune Scientific Advisory Board.

**references**

1. Boyle P, Levin B (eds). World Cancer Report 2008. Lyon, France: IARC 2008.
2. Zhong L, Coo SP, Stromberg AJ et al. Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J Thorac Oncol 2006; 1: 513–519.
3. Tan EM. Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J Clin Invest 2001; 108: 1411–1415.
4. Houghton AN. Cancer antigens: immune recognition of self and altered self. J Exp Med 1994; 180: 1–4.
5. Brichory FM, Misek DE, Yim AM et al. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci U S A 2001; 98: 9824–9829.
6. Zhang JY, Casiano CA, Peng XX et al. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev 2003; 12: 136–143.
7. Nesterova M, Johnson N, Cheadle C, Cho-Chung YS. Autoantibody biomarker opens a new gateway for cancer diagnosis. Biochim Biophys Acta 2006; 1762: 398–403.
8. Robertson JFR, Chapman CJ, Cheung KL et al. Auto-antibodies in early breast cancer. J Clin Oncol 2005; 23 (16 Suppl): 549.
9. Chapman C, Murray A, Chakrabarti J et al. Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol 2007; 18: 868–873.
10. Chapman CJ, Murray A, McEwen JE et al. Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax 2008; 63: 228–233.
11. Robertson JFR, Graves CRL, Price MR. Tumour Markers US 7,402,403, B1. Nottingham, UK: Oncimmune Ltd 1999.
12. Robertson JFR, Murray A, Chapman C, Barnes A. Calibrator for Immunoassays WO2009/081165. Nottingham, UK: Oncimmune Ltd 2007.
13. Motulsky H, Christopoulos A. Fitting Models to Biological Data Using Linear and Nonlinear Regression: A Practical Guide to Curve Fitting. New York, NY: Oxford University Press 2004.
14. Brooking H, Ananieva-Jordanova R, Arnold C et al. A sensitive non-isotopic assay for GAD65 autoantibodies. Clin Chim Acta 2003; 331: 55–59.
15. Ankelo M, Westerlund-Karlsson A, Ilonen J et al. Time-resolved fluorometric assay for detection of autoantibodies to glutamic acid decarboxylase (GAD65). Clin Chem 2003; 49: 908–915.
16. Grabar P. Hypothesis. Auto-antibodies and immunological theories: an analytical review. Clin Immunol Immunopathol 1975; 4: 453–466.
17. Grabar P. Autoantibodies and the physiological role of immunoglobulins. Immunol Today 1983; 4: 337.
18. Coenen D, Verschueren P, Westhovens R, Bossuyt X. Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein/peptide antibodies in the diagnosis of rheumatoid arthritis. Clin Chem 2007; 53: 498–504.
19. Van Campenhout CM, van Cotthem KA, Stevens WJ, De Clerck LS. Performance of automated measurement of antibodies to cyclic citrullinated peptide in the routine clinical laboratory. Scand J Clin Lab Invest 2007; 67: 859–867.
20. Biagini RE, Parks CG, Smith JP et al. Analytical performance of the AtheNA MultiLyte™ ANA assay in sera from lupus patients with multiple positive ANAs. Anal Bioanal Chem 2007; 388: 613–618.